With UK Pharma facing Brexit headwinds, could UK gov't defeat help industry by leading to a 'softer' Brexit?
The UK government’s narrow defeat (Wednesday November 13) on amendment seven of the European Union withdrawal bill, demanding that Parliament have a binding vote on the final Brexit deal, has fuelled debate on whether the UK could now be heading for a softer Brexit and what impact this will have on leading industries like UK pharma.
A recent webinar by data and analytics company GlobalData brought together industry leaders to review the reputational, economic and R&D implications of Brexit for the UK pharma sector. Key findings are summarized below.
Reputational
From a reputational point of view, the UK’s status as a first-tier drugs market could come to an end and its regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), may no longer serve as a model to other agencies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze